Aventis' assay shows promise for vCJD (variant Creutzfeldt-Jakob disease) blood screening
This article was originally published in Clinica
Executive Summary
Aventis Behring's effort to develop a blood- or plasma-screening assay for variant Creutzfeldt-Jakob Disease (vCJD) has produced promising results in a US study.